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CLINICAL SCIENCE
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Background: Future strategies aiming to achieve HIV-1 remission
are likely to target individuals with small reservoir size.
Setting: We retrospectively investigated factors associated with
HIV-1 DNA levels in European, perinatally HIV-infected children
starting antiretroviral therapy (ART) ,6 months of age.
Methods: Total HIV-1 DNA was measured from 51 long-term
suppressed children aged 6.3 years (median) after initial viral
suppression. Factors associated with log10 total HIV-1 DNA were
analyzed using linear regression.
Results: At ART initiation, children were aged median [IQR] 2.3
[1.2–4.1] months, CD4% 37 [24–45] %, CD8% 28 [18–36] %,
log10 plasma viral load (VL) 5.4 [4.4–5.9] copies per milliliter.
Time to viral suppression was 7.98 [4.6–19.3] months. After
suppression, 13 (25%) children had suboptimal response [$2
consecutive VL 50–400 followed by VL ,50] and/or experienced
periods of virological failure [$2 consecutive VL $400 followed
by VL ,50]. Median total HIV-1 DNA was 43 [6195] copies/106
PBMC. Younger age at therapy initiation was associated with
lower total HIV-1 DNA (adjusted coefﬁcient [AC] 0.12 per
month older, P = 0.0091), with a month increase in age at ART
start being associated with a 13% increase in HIV DNA.
Similarly, a higher proportion of time spent virally suppressed
(AC 0.10 per 10% higher, P = 0.0022) and the absence of viral
failure/suboptimal response (AC 0.34 for those with fail/sub-
optimal response, P = 0.0483) were associated with lower total
HIV-1 DNA.
Conclusions: Early ART initiation and a higher proportion of time
suppressed are linked with lower total HIV-1 DNA. Early ART start
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and improving adherence in perinatally HIV-1–infected
children minimize the size of viral reservoir.
Key Words: HIV-1, children, reservoir, HIV DNA, early treated,
viral load
(J Acquir Immune Deﬁc Syndr 2018;79:269–276)
INTRODUCTION
A major obstacle to HIV remission is the persistence of
virus as integrated HIV-1 DNA in long-lived cells even after
many years of suppressive antiretroviral therapy (ART).
Different methodologies have been proposed to measure
latent and persistent infection after initial viremia.1 Total HIV-1
DNA in blood CD4+ T cells and in peripheral blood mono-
nuclear cells (PBMCs) are often used as a marker of the latent
reservoir of HIV-1. Initiation of ART in the ﬁrst year of life
can minimize the size of the long-lived reservoir of HIV-1 DNA
in resting memory CD4+ T cells and limits the viral evolution.2–5
Guidelines recommend initiation of ART in all infants
infected with HIV, prioritizing those younger than 1 year.
Initiation of ART before postnatal peak decreases quickly the
viral load (VL), reduces the period of viremia, and might
favorably inﬂuence the viral reservoir in the peripheral blood
and other organs.6,7 The optimal timing for ART initiation
associated with a signiﬁcant reduction of the reservoir size
is controversial.
All reports of HIV-1 patients with long-term remission
off ART have been driven by early ART initiation, rapid viral
suppression, and small HIV reservoir size after ART.8–10
However, early ART alone is unlikely to achieve long-term,
durable viral remission in the majority of patients. In a non-
human primate model of infection, ART initiated 3 days after
simian immunodeﬁciency virus infection did not prevent the
establishment of a viral reservoir in tissues, but delayed the
viral rebound when ART was withdrawn.11 Several host
factors can inﬂuence the ﬁnal size of viral reservoir in
a patient.12 Timing of in utero infection, genetic differences,
coinfections, time to suppression, baseline CD4+ cells,
baseline VL, blips, CD4:CD8 ratio, natural killer cell
function, antibody response, innate immunity, and breadth
and magnitude of HIV-1–speciﬁc CD4+ T cells may be also
associated with the viral reservoir size.6,13,14 Better deﬁning
the inﬂuence of those factors and knowing the reservoir size
of the patients are critical points to identify potential inter-
ventions aimed at inducing ART-free HIV-1 control.
Our aim in this study was to investigate the optimal timing
for ART initiation and the factors associated with HIV-1 DNA
in early treated European HIV-1 perinatally infected children.
This study was conducted within the frame of EPIICAL
project. EPIICAL is an international consortium whose ﬁrst
aim is to identify proﬁles of viral control. These proﬁles will
be used as end points in future proof of concept studies with
novel HIV immunotherapeutic strategies.15
METHODS
This is a retrospective, multicenter observational sur-
vey. Data were retrospectively collected from the standard-
ized databases of 5 European cohorts in 3 countries (see Table
1, Supplemental Digital Content, http://links.lww.com/QAI/
B190).2,4,16–18 DNA determinations were performed between
2000 and 2016 as part of clinical care in 5 of the EPIICAL
European partners.2,4,16–20 Data were gathered between
September 2016 and July 2017. The study was approved by
the competent ethics committees.
Eligible participants were HIV-1 perinatally infected
children or adolescents who started ART in the ﬁrst 6 months
of life, achieved viral suppression ($2 consecutive HIV RNA
,50 copies/mL) on ART, and had any DNA determination
after viral suppression. Children were excluded if they had
poor adherence to the ART during the ﬁrst year of life.
The primary outcome was total HIV-1 DNA copies/106
PBMC. If patients had .1 DNA measurements, only the last
DNA available data were included.
Variables investigated included age at ART start,
duration of ART by HIV DNA determination, AIDS diagno-
sis, initial ART regimen, cohort, age at HIV DNA measure-
ment, baseline VL, baseline immunological data (CD4% and
count, CD8%, CD4/CD8 ratio, and total lymphocyte count),
and postsuppression VL features (blips, spikes, suboptimal
response, and failure). Variables considered a priori to be
associated with HIV-1 DNA such as time to initial VL
suppression and proportion of time virally suppressed were
also included in the analysis.
Baseline VL deﬁned as the closest VL measurement
within 6 months before and 1 week after ART start, baseline
CD4%, CD8%, CD4:CD8 ratio, lymphocyte count deﬁned as
closest measurement within 6 months before and 1 month
after ART start, blips deﬁned as single VL 50–400 copies per
milliliter preceded and followed by VL ,50, high magnitude
blips (ie, spikes) deﬁned as single VL $400 preceded and
followed by VL ,400, and suboptimal viral response deﬁned
as $2 consecutive VL 50–400 followed by VL ,50.
Virological failure was deﬁned as $2 consecutive VL
$400. The following composite variables were also consid-
ered: suboptimal viral response or virological failure, blips or
spikes, spikes or suboptimal viral response, and blips or
spikes or suboptimal viral response. Blips, spikes, suboptimal
response, and virological failure were counted from initial VL
suppression to HIV DNA measurement.
Laboratory Methods
Before 2003, standard HIV-1 RNA testing (Amplicor
HIV-1 monitor; Roche Diagnostic Systems, Branchburg, NJ)
was used in all laboratories, with routine lower limit of
detection (LOD) of ,400 copies per milliliter and ultrasen-
sitive LOD of ,50 copies per milliliter. Since 2003,
participating laboratories use ultrasensitive measurements
with an LOD of 20–50 copies per milliliter.
Total HIV-1 DNA
In the United Kingdom, CD4+ T cells were enriched
from frozen PBMC samples by negative selection (Dyna-
beads; Thermoﬁsher Scientiﬁc, MA) to a purity of more than
97%. CD4+ T-cell DNA was extracted (Qiagen, Hilden,
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Germany) and used as input DNA for droplet digital polymerase
chain reaction (ddPCR; detection limits ,3–4 copies/106 cells).
Cell copy number and total HIV-1 DNA levels were quantiﬁed
in triplicate using previously published assays.4
In Spain, CD4+ T cells were puriﬁed from PBMC by
negative immunomagnetic separation (CD4+ T Cell Isolation
Kit; Miltenyi Biotech, Auburn, CA), and lysed extracts were
used to measure cell-associated total HIV-1 DNA by ddPCR
with 59LTR or Gag primers and probes, depending on the
efﬁciency of detection in each patient (detection limits ,3–4
copies/106 cells). DNA was calculated per 106 CD4+ T cells
and converted into 106 PBMC after knowing average survival
PBMC under the same conditions (70%).16,19
In Padova, PBMCs were isolated from peripheral blood
by centrifugation on Ficoll-Paque (Pharmacia, Uppsala, Swe-
den) gradient and cryopreserved in liquid nitrogen until use. Cell
lysates were used to estimate cell-associated HIV-1.21 HIV-1
DNA copies were quantiﬁed by ddPCR (QX200TM Droplet
Digital TM PCR; Biorad, Bio-Rad Laboratories, Inc., Hercules,
CA; detection limits 1 copy/105 cells), using primer pair and
probe that recognizes a conserve region of the gag gene, and
primer pair and probe that detects the housekeeping b–actin
gene to normalize for cell equivalents.17,21
In Rome, total cell DNA was extracted from PBMC
pellets with High Pure PCR Template Preparation Kit (Roche
Molecular Biochemicals, Germany). Total HIV-DNA was
TABLE 1. Virological and Immunological Characteristics
CHIPS/CHERUB-
YC
(n = 8)
CoRISpeS-CAT
(n = 6)
CoRISpeS-
MADRID
(n = 10) Padova (n = 12) Rome (n = 15) P† All_Cohorts
Median (IQR) [N]
Age at ART start
(mo)
4 (2–5) [n = 8] 2 (1–2) [n = 6] 2 (0–2) [n = 10] 2 (2–4) [n = 12] 3 (2–5) [n = 15] 0.1068 2 (1–4) [n = 51]
Age at HIV DNA
measurement
(years)
10 (9–13) [n = 8] 6 (4–7) [n = 6] 9 (7–11) [n = 10] 5 (4–12)
[n = 12]
5 (3–13) [n = 15] 0.1669 7 (4–11) [n = 51]
Duration of ART
by HIV DNA
(years)
10 (9–12) [n = 8] 6 (4–7) [n = 6] 9 (6–11) [n = 10] 5 (4–11)
[n = 12]
5 (3–13) [n = 15] 0.1704 7 (4–11) [n = 51]
Time to VL
suppression
(months)
8 (5–10) [n = 8] 7 (5–10) [n = 6] 7 (4–47) [n = 10] 14 (6–30)
[n = 12]
6 (5–10) [n = 14] 0.7776 8 (5–19) [n = 50]
Proportion of
time VL
suppressed (%)
91 (85–95) [n = 8] 93 (84–94) [n = 6] 67 (59–82)
[n = 10]
71 (39–88)
[n = 12]
91 (74–95) [n = 14] 0.0735 85 (61–94) [n = 50]
HIV DNA
copies/106
PBMC
250 (95–334)
[n = 8]
21 (14–47) [n = 6] 8 (3–20) [n = 10] 26 (5–44)
[n = 12]
188 (27–283)
[n = 15]
0.0006 43 (6195) [n = 51]
Baseline VL
(copies/ml)
224,383 (437,56–
500,000) [n = 6]
650,000 (391,300–
750,000) [n = 5]
21–500 (11,084–
160,000) [n = 8]
750,000
(100,000–1.00e
+07)
[n = 11]
500,000 (21,800–
500,000) [n = 9]
0.1141 247,387
(250,00–750,000)
[n = 39]
Baseline log10 VL
(copies/ml)
5.3 (4.6–5.7)
[n = 6]
5.8 (5.6–5.9)
[n = 5]
4.3 (4.0–5.2)
[n = 8]
5.9 (5–7)
[n = 11]
5.7 (4.3–5.7)
[n = 9]
0.1141 5.4 (4.4–5.9)
[n = 39]
Baseline
immunological
data
CD4% 21 (15–33) [n = 7] 39 (35–47) [n = 5] 44 (44–47) [n = 5] 32 (27–45)
[n = 11]
42 (31–54) [n = 13] 0.0716 37 (24–45) [n = 41]
CD8% 37 (32–44) [n = 6] 23 (16–26) [n = 5] 25 (18–28) [n = 5] 30 (18–36)
[n = 9]
28 (15–33) [n = 11] 0.1903 28 (18–36) [n = 36]
CD4%/CD8%
ratio
0.61 (0.48–.89)
[n = 6]
1.7 (1.6–1.81) [n = 5] 1.57 (0.96–2.61)
[n = 5]
0.89 (0.78–3.1)
[n = 9]
1.4 (0.68–2.1)
[n = 11]
0.1299 1.32 (0.73–2.2)
[n = 36]
CD4 count
(cells/mm3)*
460 (195–1092)
[n = 7]
— 2458 (1282–3448)
[n = 4]
2195 (1450–2882)
[n = 8]
2282 (503–3629)
[n = 10]
0.0087 1495 (620–2885)
[n = 29]
Total lymphocyte
count
(cells/mm3)
2800 (2190–3000)
[n = 7]
— 6061 (4160–6754)
[n = 4]
7055 (5665–8840)
[n = 8]
5965 (1810–7070)
[n = 10]
0.0088 5600 (2800–7070)
[n = 29]
Baseline VL: closest VL measurement within 6 months before and 1 week after ART start.
Baseline CD4%, CD8%, and lymphocyte count: closest measurement within 6 months before and 1 month after ART start.
Viral suppression: $2 consecutive VL ,50 HIV RNA copies/mL.
Duration of ART by HIV DNA (years): time in years from ART start to HIV DNA measurement.
Proportion of time VL suppressed (%): duration of VL suppression from ART start to HIV DNA measurement/duration of ART by HIV DNA · 100. For calculation of duration of
VL suppression, single-isolated blips or spikes were allowed and counted as time suppressed.
*CD4 count calculation: CD4% · lymphocyte count/100.
†The Kruskal–Wallis test.
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quantiﬁed by RT-PCR, using 59 nuclease assay in the long
terminal repeat (LTR) region of HIV-1 (reference sequence
HXB2) performed on a LightCycler v3.5 (Roche Molecular
Biochemicals, IN).
Statistics
Data were analyzed using Stata software, version 14.2
(Stata Statistical Software: StataCorp LP, Release 14, College
Station, TX). All patients with available DNA data from the
cohorts of United Kingdom, Italy, and Spain were
included.4,16–18 HIV-1 DNA was log10 transformed and
regressed on putative predictors. For the purpose of the
analysis, if the original value was below the detection limit,
the value was replaced by half the detection limit. Relating
baseline VL, if original values were below lower detection
limit, the value was replaced by half detection limit; if
original values were over upper detection limit, they were
replaced by upper limit value. For descriptive analysis,
categorical variables are presented with frequency distribu-
tions (both absolute and relative). Continuous variables are
summarized as median, interquartile range [IQR].
Factors associated with log10 total HIV-1 DNA levels
were investigated using linear regression. Regression diag-
nostics were examined to ensure that all model assumptions
were met, particularly normality of residuals further tested
using the Shapiro–Wilk test.
The confounding effects of cohort and age at DNA
measurement were taken into account. Variables signiﬁcantly
associated with log10 total HIV-1 DNA levels at P , 0.10
were included in a multivariable model, using backward
stepwise elimination (exit probability P = 0.05) to reach the
ﬁnal model. Sensitivity analyses were performed excluding:
(1) 5 children who experience virological failure for a period
after initial suppression but suppressed for years until HIV-1
determination; and (2) 6 children who took more than 3 years
to attain initial VL suppression after ART start.
To further conﬁrm results from complete case analysis,
univariable and multivariable analyses were performed using
multiply imputed data. Missing data in baseline CD4%,
CD8%, VL, and total lymphocyte count were multiply
imputed (n = 25) using multiple imputation by
chained equations.
RESULTS
In total, 51 children were included in the analysis. Fifty-
ﬁve percent of the children were female, and 29% had ever
had an AIDS diagnosis. Ten out of 15 (66%) patients with
AIDS diagnosis had a conﬁrmed AIDS-deﬁning event before
ART start. Baseline characteristics of patients at initiation of
ART are summarized in Table 2, Supplemental Digital
Content, http://links.lww.com/QAI/B190 and Table 1, and
Table 3, Supplemental Digital Content, http://links.lww.com/
QAI/B190. A total of 53% were from Italy, 31% from Spain,
and 16% were from United Kingdom. Total HIV-1 DNA
varied by cohort, with the highest levels in CHIPS/CHERUB-
YC and Rome (Figs. 1 and 2). Hence, all analyses were
adjusted for cohort and age at HIV-1 DNA determination.
Median [IQR] baseline VL was 247,387 [25,000–
750,000] copies per milliliter. Median time to suppression
was 8 [5–19] months. The participants were virally sup-
pressed for a median of 85% (61–94) of time before DNA
determination, which was 6 years [3–8] after initial viral
suppression. The median [IQR] age at DNA determination
was 7 [4–11] years. Median total HIV-1 DNA level was 43
[6195] copies/106 PBMC.
FIGURE 1. Distribution of HIV-1 DNA by cohort. Log10 HIV-1
DNA varies by cohort with highest levels in CHIPS and ROME
(Kruskal–Wallis P value = 0.0006).
FIGURE 2. Two-way scatter plot illustrating graphically the
relationship between HIV DNA and age at ART start. This plot
illustrates the significant results from linear regression analysis
shown in main results table.
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After initial viral suppression, 45% of children had $1
blip, 22% had $1 spike, and 20% had suboptimal viral
response. Five patients (10%) had VL failure.
When composite variables were considered, 13 (25%)
children had suboptimal response and/or experienced periods
of virological failure. Other composite variables are summa-
rized in Table 2.
In multivariable analysis, lower total HIV-1 DNA was
associated with younger age at ART start (adjusted coefﬁcient
0.12; 95% CI: 0.03 to –0.21, P = 0.0091), with a month
increase in age at ART start being associated with a 13%
increase in HIV-1 DNA.
Similarly, a higher proportion of time spent virally
suppressed (adjusted coefﬁcient 20.10, 95% CI 20.17 to
20.04, per 10% higher, P = 0.0022) and the absence of viral
failure/suboptimal response (adjusted coefﬁcient 0.34, 95%
CI: 0.00 to 0.67, for those with fail/suboptimal response, P =
0.0483) were associated with lower total HIV-1 DNA (Table
3). In addition, the effect of cohort remained signiﬁcant with
highest total HIV-1 DNA values in the cohorts from the
CHIPS/CHERUB-YC (United Kingdom) and Rome. These
associations remained signiﬁcant after adjustment for the
other factors in the multivariable model.
Although univariable analysis suggested an association
between baseline immunological data (CD4, CD4:CD8 ratio,
and total lymphocyte; P = 0.05–0.10) and also AIDS
diagnosis (P , 0.05) and total DNA, these associations failed
to reach signiﬁcance after adjustment. Missing data rates in
immunological data (CD4%, CD8%, and total lymphocyte) and
VL ranged from 20% to 43%. Sensitivity analyses (excluding 5
children with viral failure, or 6 who took $3 years to suppress)
as well as analyses of imputed immunological data produced
similar results. Therefore, these children were not excluded. Data
relating the 6 patients who took $3 years to suppress are
provided in Table 4, Supplemental Digital Content, http://links.
lww.com/QAI/B190.
DISCUSSION
In this study, we demonstrate that children who start
ART earlier in life and remain suppressed without blips or
treatment failure have the lowest viral reservoir, as they
mature through childhood. To the best of our knowledge, this
is the study with the largest number of perinatally infected
children starting ART ,6 months of age in Europe.
We consider that this is the ideal population to
investigate immunotherapeutic strategies toward HIV remis-
sion.22 Understanding conditions associated with different
levels of HIV-1 DNA could critically help in the design of
future trials.
Previous reports have shown signiﬁcant differences in
HIV-1 DNA measurements between groups of children
TABLE 2. Summary of VL Features After Initial Confirmed Suppression
CHIPS CORISPE-CAT Madrid Padova Rome
P*
Total
No. % No. % No. % No. % No. % No. %
Blip 0.0012
No 1 12.5 6 100 8 80 3 25 10 67 28 55
Yes 7 87.5 0 0 2 20 9 75 5 33 23 45
Spike 0.0904
No 7 87.5 5 83 8 80 6 50 14 93 40 78
Yes 1 12.5 1 17 2 20 6 50 1 7 11 22
Suboptimal VL response 0.2416
No 5 62.5 6 100 7 70 9 75 14 93 41 80
Yes 3 37.5 0 0 3 30 3 25 1 7 10 20
VL failure 0.4879
No 8 100 6 100 8 80 10 83 14 93 46 90
Yes 0 0 0 0 2 20 2 17 1 7 5 10
Composite variables
Blip/spike 0.0068
No 1 12.5 5 83 6 60 2 17 10 67 24 47
Yes 7 87.5 1 17 4 40 10 83 5 33 27 53
Spike/suboptimal response 0.1041
No 5 62.5 5 83 5 50 5 42 13 87 33 65
Yes 3 37.5 1 17 5 50 7 58 2 13 18 35
Fail/suboptimal response 0.2654
No 5 62.5 6 100 6 60 8 67 13 87 38 75
Yes 3 37.5 0 0 4 40 4 33 2 13 13 25
Blip/spike/suboptimal response 0.0046
No 0 0 5 83 4 40 2 17 9 60 20 39
Yes 8 100 1 17 6 60 10 83 6 40 31 61
*The Kruskal–Wallis test.
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treated in the ﬁrst month of life versus children treated
late.16,23–26 Rather than grouping patients in subsets, we have
quantiﬁed the weight of each month delay in the initiation of
ART after birth and the impact on the reservoir size. The
results show that for each month delayed with treatment,
HIV-1 DNA increases by 13% (P = 0.009).
Deﬁning the interplay between timing of ART, size of
reservoir, and duration of viral suppression is critical. Our
study conﬁrms the relevance of early ART initiation as well
as long-term maintenance of stable viral suppression as key
factors leading to lower size of viral reservoir.27 Results
suggest that for each 10% increase in proportion of time
suppressed during follow-up, HIV-1 DNA decreases by 10%.
Conversely to other studies, we did not demonstrate
a correlation between time to suppression and HIV-1 DNA
levels.23 A fast control is probably not enough for achieving
a small reservoir. Still, this approach is currently under
investigation in studies as IMPAACT 1115 (NCT02140255).
The levels of DNA in our cohort are higher than HIV-1
DNA levels found in selected children who achieved
virological control before 1 year of age.5 However, in the
children who started ART in the ﬁrst 2 weeks of life, the HIV-
1 DNA was extraordinarily low (,1 log10/106 PBMC),
similarly to the very early treated children described by
Luzuriaga et al.24
Total HIV-1 DNA in PBMCs is not a perfect marker of
reservoir size, as PCR methods can detect up to 90%
defective proviruses.28,29 In one report, of the 9 viral
outgrowth assays performed for early treated youth, only 1
of 20 replicates tested positive for replication-competent
virus.24 Although it is tempting to hypothesize that children
with,10 copies/106 PBMC may have virtually no replication
competent virus, replication-competent HIV-1 can be recov-
ered from individuals with HIV-1 DNA levels below 2
copies/106 PBMC.30 Rebound of viremia may follow after
cessation of ART despite very low levels of replication-
competent HIV-1, suggesting the stochastic nature of virus
rebound.1,16 Further assays as measurements after rounds of
T-cell activations, sequencing, and measurement of reservoir
in tissues should be tested in the future.31
Residual HIV-1 replication has been suggested to
contribute to the maintenance of the HIV-1 reservoir.24
According to our results, brief intermittent viremia (ie, blips
and spikes) did not have a long-term impact; however,
prolonged low-grade viremia and/or virological failure led
to higher levels of HIV-1 DNA.
Power was also insufﬁcient to conﬁrm an association
between HIV-1 DNA and baseline immunological data.
However, CD4:CD8 ratio (P = 0.0479 in the univariate
model) seemed a potential predictor for a higher reservoir. Of
note, CD4:CD8 has also been associated with T-cell activa-
tion, senescence, and exhaustion.32
In our study, the effect of site remained signiﬁcant
with highest HIV-1 DNA values noted in the United
Kingdom and Rome. Also, signiﬁcant cohort differences
were found for AIDS diagnosis, CD4+ counts, total
lymphocyte counts, and blips. However, there were no
signiﬁcant differences for year of ART initiation. UK
children presented with more AIDS diagnosis, lower
baseline CD4, and total lymphocyte counts.
TABLE 3. Factors Associated With Lower Total HIV-1 DNA
Factors
Univariable Model Multivariable Model
N % Diff b (95% CI) P % Diff b* (95% CI) P†
Age at ART start (per mo older) 51 27.7 0.24 (0.14 to 0.35) 0.00002 12.7 0.12 (0.03 to 0.21) 0.0091
Age at HIV DNA measurement (per yr older) 51 5.3 0.05 (0.00 to 0.10) 0.0395 — — —
Duration of ART by HIV DNA (per yr higher) 51 5.0 0.05 (20.00 to 0.10) 0.0528 — — —
Proportion of time suppressed (per 10% higher)† 50 23.5 20.04 (20.13 to 0.06) 0.4454 29.9 20.10 (20.17 to 20.04) 0.0022
Time to VL response (per mo longer)† 50 0.2 0.00 (20.01 to 0.01) 0.6976 — — —
AIDS diagnosis 48
Yes [Ref: No] 15 93.2 0.66 (0.20 to 1.11) 0.0054 — — —
Composite: fail/suboptimal response 51
Yes [Ref: No] 13 55.0 0.44 (20.05 to 0.92) 0.0758 40.1 0.34 (0.00 to 0.67) 0.0483
Baseline immunological data
CD4 count (per 500 cells higher) 27 28.7 20.09 (20.18 to 0.00) 0.0541 — — —
CD4% (per 10% higher) 41 213.2 20.14 (20.29 to 0.01) 0.0625 — — —
CD4/CD8 ratio (per unit higher) 36 219.0 20.21 (20.42 to 20.00) 0.0479 — — —
Total lymphocyte (per 500 cells higher) 27 24.3 20.04 (20.09 to 0.00) 0.0678 — — —
Cohort [Ref: Rome] 51
CHIPS/CHERUB-YC 8 43.1 0.36 (20.19 to 0.90) 0.1934 29.5 0.26 (20.17 to 0.69) 0.2326
CORISPE-CAT 6 249.5 20.68 (21.29 to 20.08) 0.0270 238.6 20.49 (20.97 to 20.01) 0.0468
CORISPE-MADRID 10 264.1 21.02 (21.53 to 20.52) 0.0002 268.3 21.15 (21.59 to 20.71) 0.0000
Padova 12 246.2 20.62 (21.10 to 20.14) 0.0130 259.6 20.91 (21.30 to 20.51) 0.0000
b, unadjusted regression coefﬁcient estimates; 95% CI, conﬁdence interval; % Diff, % difference in HIV-1 DNA: a unit change in factors investigated is associated with a Y%
change in HIV-1 DNA eg, a month increase in age at ART start is associated with a 27.7% increase in HIV-1 DNA.
b*, adjusted regression coefﬁcient estimates; P-value*, adjusted for the other factors included in the multivariable model.
Criteria for inclusion into the multivariable model: univariable model p-value , 0.10 or †deﬁned a priory.
P-values in bold are those that reached statistical signiﬁcance P , 0.05.
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Median of ART start in United Kingdom and Rome
was 1–2 months later than in other cohorts (Table 1). At
that time point, treatment policy in United Kingdom was to
initiate ART only when children were symptomatic.
Although 1–2 months of delay may seem a small amount
of time, ﬁrst 3 months of life may be key for the
immunological response to HIV.7 Bearing in mind that
each month of delay in initiating ART implies a 13%
increase in the size of the reservoir, it is normal that in the
UK cohort the reservoir is at least 25% higher than in Italy
and Spain.
Time from ART to HIV-1 DNA measurement was
longer in the United Kingdom than in other cohorts,
because of DNA measurement at older age. This is why
proportion of time spent suppressed was deemed as a more
accurate indicator of effective ART, accounting for dura-
tion of VL suppression and duration of ART by HIV
DNA measurement.
Numbers starting nonnucleoside reverse transcriptase
inhibitor–based or protease inhibitor–based regimen by
cohort are low for comparison. In general, UK children had
higher HIV DNA, regardless of initial ART regimen. We
were aware of a signiﬁcant cohort effect, and adjustment for
cohort was done in the ﬁnal multivariable analysis.
This study had some operational difﬁculties, as deter-
minations were performed by different laboratories. Limita-
tions of this study include different PCR techniques and
cutoff limits used for VL and DNA, which may have had an
inﬂuence in the homogeneity of data and results. Both ddPCR
for HIV-1 in PBMCs and ddPCR for HIV-1 in CD4+ T cells
detect the same viral species (replication-competent and
replication-defective). However, the former analyzes not only
CD4+ T cells but also monocytes/macrophages. An adjust-
ment from UK and Spain data was necessary for comparison,
taking into account the number of viable PBMC of the
analyzed samples. In comparative studies, the levels of HIV-1
DNA in unfractionated PBMCs and in puriﬁed resting CD4+
T cells showed a strong correlation (r = 0.78, P = 0.0004).1 In
any case, there is a need for standardization of assays used to
measure the reservoir, especially if these are to be used in
future clinical trials.
We had no information about additional host factors
that may inﬂuence the reservoir size. However, cross-
sectional and prospective ongoing studies conducted within
the EPIICAL consortium will address other factors.
The small sample size limited the power to identify
other factors associated with total HIV-1 DNA level after
viral suppression. Longitudinal data to assess reservoir decay,
and complete serology data were also missing.
Despite these limitations, this is one of the studies with
the highest number of cases of early treated HIV-infected
children measuring the viral reservoir and evaluating the
associated factors, so far.
In conclusion, a long-term lower total HIV-1 DNA was
found to be associated with starting ART earlier and with
spending a higher proportion of time suppressed. This study
provides further evidence to support current guidelines that
recommend treatment with ART as soon as possible in
perinatally infected children.
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